myoscience
10.07.2012 14:00
---------------------------------------------------------------------------
REDWOOD CITY, Calif., 2012-07-10 14:00 CEST (GLOBE NEWSWIRE) --
The newest generation of myoscience's novel device technology has received FDA
clearance for the treatment of pain.
myoscience's patented technology precisely delivers cold to targeted nerves.
The cold induces a hibernating state resulting in a temporary interruption of
nerve signaling to sensory receptors or muscle tissue. The device uses the
power of cold to achieve an immediate result with nothing left behind in the
patient. The myoscience device received CE approval and a medical device
license from Health Canada in 2011.
The hand-held device is intended for use in the physician's office and
represents a breakthrough advance in the treatment of pain. The myoscience
technology can address multiple indications in a targeted treatment with no
systemic side effects or addictive potential.
'FDA clearance for our device in the US provides myoscience with a platform
technology on which to grow our company by addressing further indications and
an expanding geography,' said Clint Carnell, Chief Executive Officer of
myoscience.
About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy(TM),
the pre-eminent treatment for nerves. Focused Cold Therapy is currently
approved in Europe and Canada for temporary wrinkle reduction, temporary pain
reduction and treatment of dermatologic conditions. The myoscience technology
has also been cleared in the United States for use in pain management and
general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13581
CONTACT: Clint Carnell
650/421-0605
News Source: NASDAQ OMX
10.07.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: myoscience
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9902131674
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Next Generation of myoscience Device Receives FDA Clearance for Pain Management
| Source: EQS Group AG